The Testosterone Bioavailability Index (TBI) is a calculated clinical metric used to estimate the fraction of circulating testosterone that is biologically active and readily available to target tissues. This index is typically derived from the concentrations of total testosterone, sex hormone-binding globulin (SHBG), and albumin. It provides a more accurate assessment of androgen status than total testosterone alone, as SHBG tightly binds a significant portion of the hormone, rendering it temporarily inactive.
Origin
This term is a fundamental concept in clinical endocrinology, arising from the necessity to accurately assess androgen deficiency and excess. The TBI is an evolution of calculating Free Testosterone, offering a standardized and reliable method to account for protein binding dynamics. It is a crucial tool in diagnosing conditions related to hormonal dysregulation.
Mechanism
The index calculation utilizes the law of mass action to determine the equilibrium between bound and unbound testosterone. The hormone is either weakly bound to albumin or tightly bound to SHBG; only the free and albumin-bound fractions are considered bioavailable. Clinically, factors that alter SHBG levels, such as insulin status or thyroid function, directly impact the TBI, thus modulating the effective androgenic signal.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.